From Epilepsy to Autism
In the world of endocannabinoid science, there are 3 areas of large response that are getting attention. Those are autoimmune disorders, cancers, and neurological diseases. Preclinical (in vivo or in vitro) research is exploding in these areas, and some cannabinoid based therapies have even passed FDA Approval for Dravet and Lennox-Gateaux Syndrome. Since many areas are relaxing restrictions on therapeutic access to cannabis, patients and their family members have the option of finding cheaper and more comprehensive alternatives to these FDA approved products. Below are some of the studies regarding cannabinoids and individual neurological disorders.
This is not intended as medical advice or legal advice. Please take these to your medical team so you can make educated and informed decisions.
Autism
Hemiplegic Migraine
Parkinson’s
CB1 cannabinoid receptor signaling in Parkinson’s disease
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study